| Patent application number | Description | Published |
|---|
| 20080274122 | Plks as Modifiers of the Beta Catenin Pathway and Methods of Use - Human PLK genes are identified as modulators of the beta catenin pathway, and thus are therapeutic targets for disorders associated with defective beta catenin function. Methods for identifying modulators of beta catenin, comprising screening for agents that modulate the activity of PLK are provided. | 11-06-2008 |
| 20090013416 | PDES AS MODIFIERS OF THE IGFR PATHWAYS AND METHODS OF USE - Human PDE genes are identified as modulators of the IGFR pathway and thus are therapeutic targets for disorders associated with defective IGFR function Methods for identifying modulators of IGFR comprising screening for agents that modulate the activity of PDE are provided | 01-08-2009 |
| 20090025096 | P4HAS AS MODIFIERS OF THE IGFR PATHWAY AND METHODS OF USE - Human P4HA genes are identified as modulators of the IGFR pathway, and thus are therapeutic targets for disorders associated with defective IGFR function. Methods for identifying modulators of IGFR, comprising screening for agents that modulate the activity of P4HA are provided. | 01-22-2009 |
| 20090028844 | GALNTS AS MODIFIERS OF THE IGFR PATHWAY AND METHODS OF USE - Human MIGFR genes are identified as modulators of the IGFR pathway, and thus are therapeutic targets for disorders associated with defective IGFR function. Methods for identifying modulators of IGFR, comprising screening for agents that modulate the activity of MIGFR are provided. | 01-29-2009 |
| 20090068186 | MAP3Ks as modifiers of the p53 pathway and methods of use - Human MAP3K genes are identified as modulators of the p53 pathway, and thus are therapeutic targets for disorders associated with defective p53 function. Methods for identifying modulators of p53, comprising screening for agents that modulate the activity of MAP3K are provided. | 03-12-2009 |
| 20090142272 | Pfks as modifiers of the igfr pathway and methods of use - Human PFK genes are identified as modulators of the IGFR pathway, and thus are therapeutic targets for disorders associated with defective IGFR function. Methods for identifying modulators of IGFR, comprising screening for agents that modulate the activity of PFK are provided. | 06-04-2009 |
| 20090149413 | RORS as Modifiers of the p21 Pathway and Methods of Use - Human ROR genes are identified as modulators of the p21 pathway, and thus are therapeutic targets for disorders associated with defective p21 function. Methods for identifying modulators of p21, comprising screening for agents that modulate the activity of ROR are provided. | 06-11-2009 |
| 20090202563 | C20ORF23 as modifier of the IGFR pathway and methods of use - Human C20ORF23 genes are identified as modulators of the IGFR pathway, and thus are therapeutic targets for disorders associated with defective IGFR function. Methods for identifying modulators of IGFR, comprising screening for agents that modulate the activity of C20ORF23 are provided. | 08-13-2009 |
| 20100159470 | SCDs As Modifiers of the p53 Pathway and Methods of Use - Human SCD genes are identified as modulators of the p53 pathway, and thus are therapeutic targets for disorders associated with defective p53 function. Methods for identifying modulators of p53, comprising screening for agents that modulate the activity of SCD are provided. | 06-24-2010 |
| 20100325743 | Marks as modifiers of the p53 pathway and methods of use - Human MARK genes are identified as modulators of the p53 pathway, and thus are therapeutic targets for disorders associated with defective p53 function. Methods for identifying modulators of p53, comprising screening for agents that modulate the activity of MARK are provided. | 12-23-2010 |
| 20110059066 | PAKs as Modifiers of the CHK Pathway and Methods of Use - Human PAK genes are identified as modulators of the CHK pathway, and thus are therapeutic targets for disorders associated with defective CHK function. Methods for identifying modulators of CHK, comprising screening for agents that modulate the activity of PAK are provided. | 03-10-2011 |
| 20110159508 | GFATS as Modifiers of the P53 Pathway and Methods of Use - Human GFAT genes are identified as modulators of the p53 pathway, and thus are therapeutic targets for disorders associated with defective p53 function. Methods for identifying modulators of p53, comprising screening for agents that modulate the activity of GFAT are provided. | 06-30-2011 |
